
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc. has reported a significant increase of 41% quarter-over-quarter in its NeXT Personal Dx volumes for Q4 2025, which exceeds prior expectations and points to a robust demand trajectory. The company's partnership with Tempus is anticipated to further accelerate marketing efforts for its tests, potentially driving additional volume growth in the upcoming quarters. Furthermore, the recent acquisition of Medicare coverage and pricing for the NeXT Personal MRD test is expected to enhance its market presence, as strong performance in detecting minimal residual disease demonstrates the product's value in early cancer recurrence detection.
Bears say
Personalis Inc. has faced a negative outlook primarily due to a downgrade in its revenue guidance for Q4 2025, attributed to a general slowdown in the biopharma sector and logistical issues with global sample handling. The company's reliance on its genetic sequencing and analytics solutions has led to significant losses, accompanied by debt on its balance sheet, raising concerns about its ability to achieve future profitability. Additionally, the decline in revenue from pharma services, particularly linked to reduced activity in Moderna's Phase III melanoma trial, further reinforces the challenges the company is facing in sustaining its operations and growth.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares